A federal grand jury indicted Berkeley Premium Nutraceuticals, the company's President Steve Warshak, his mother and five additional defendants and co-conspirators on a total of 112 criminal charges Sept. 20. Warshak engaged in conspiracy to commit mail, wire and bank fraud, money laundering, conspiracy to obstruct proceedings before FTC and other criminal acts, U.S. Attorney for the Southern District of Ohio Gregory Lockhart alleges. Warshak, et al., defrauded consumers of more than $100 mil., according to Lockhart. If convicted, the defendants are expected to forfeit assets including several parcels of land, vehicles, and the contents of numerous bank and investment accounts, according to the filing. Berkeley, marketer of male enhancement supplement Enzyte, settled with the Attorney Generals of six states in March for $2.5 mil. (1"The Tan Sheet" March 6, 2006, p. 8). Earlier this month, the Cincinnati, Ohio-based firm issued a press release asserting they had reduced consumer complaints by 90% (2"The Tan Sheet" Sept. 11, 2006, In Brief)....
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
